PAVmed (PAVM) Competitors $0.59 -0.01 (-1.19%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.59 +0.00 (+0.17%) As of 07/7/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAVM vs. NEPH, SPAI, ECOR, POCI, QTI, MODD, PYPD, NMTC, COCH, and TMDIFShould you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Nephros (NEPH), Safe Pro Group (SPAI), electroCore (ECOR), Precision Optics (POCI), QT Imaging (QTI), Modular Medical (MODD), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), Envoy Medical (COCH), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry. PAVmed vs. Its Competitors Nephros Safe Pro Group electroCore Precision Optics QT Imaging Modular Medical PolyPid NeuroOne Medical Technologies Envoy Medical Titan Medical Nephros (NASDAQ:NEPH) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do institutionals and insiders hold more shares of NEPH or PAVM? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 7.3% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend NEPH or PAVM? Nephros presently has a consensus target price of $5.00, suggesting a potential upside of 22.55%. PAVmed has a consensus target price of $19.00, suggesting a potential upside of 3,120.34%. Given PAVmed's higher probable upside, analysts clearly believe PAVmed is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor NEPH or PAVM? In the previous week, Nephros had 1 more articles in the media than PAVmed. MarketBeat recorded 1 mentions for Nephros and 0 mentions for PAVmed. Nephros' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score. Company Overall Sentiment Nephros Neutral PAVmed Neutral Which has more risk & volatility, NEPH or PAVM? Nephros has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Which has higher valuation and earnings, NEPH or PAVM? PAVmed has lower revenue, but higher earnings than Nephros. PAVmed is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.05$70K$0.0758.29PAVmed$2.99M3.37$39.79M$0.710.83 Is NEPH or PAVM more profitable? PAVmed has a net margin of 3,711.54% compared to Nephros' net margin of 5.16%. Nephros' return on equity of 9.43% beat PAVmed's return on equity.Company Net Margins Return on Equity Return on Assets Nephros5.16% 9.43% 7.20% PAVmed 3,711.54%N/A -42.29% SummaryNephros beats PAVmed on 7 of the 13 factors compared between the two stocks. Get PAVmed News Delivered to You Automatically Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAVM vs. The Competition Export to ExcelMetricPAVmedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.21M$6.86B$5.52B$9.02BDividend YieldN/A1.21%5.24%4.08%P/E Ratio0.8325.5527.1920.04Price / Sales3.37109.22395.22100.83Price / CashN/A21.4826.2128.59Price / Book-0.644.727.925.55Net Income$39.79M$173.18M$3.17B$248.49M7 Day Performance-4.24%0.34%1.79%4.87%1 Month Performance-6.62%-2.74%1.28%6.63%1 Year Performance-25.72%25.56%33.32%20.38% PAVmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAVMPAVmed3.904 of 5 stars$0.59-1.2%$19.00+3,120.3%-16.7%$10.21M$2.99M0.8390Gap UpNEPHNephros0.8398 of 5 stars$4.09+6.0%$5.00+22.2%+96.2%$40.92M$14.16M58.4430Positive NewsHigh Trading VolumeSPAISafe Pro GroupN/A$2.75+3.0%N/AN/A$40.51M$2.17M-3.4011Positive NewsGap DownECORelectroCore2.3116 of 5 stars$5.28-3.1%$25.50+383.0%-4.7%$40.44M$25.18M-3.3850POCIPrecision OpticsN/A$4.90-0.4%N/A-22.0%$37.72M$19.10M-5.5180QTIQT ImagingN/A$1.39+17.8%N/A+99.5%$37.72M$4.00M0.00N/AGap DownMODDModular MedicalN/A$0.75+9.7%N/A-51.1%$36.83MN/A-1.4620PYPDPolyPid2.0651 of 5 stars$3.53-1.1%$11.80+234.3%-13.8%$36.38MN/A-0.8280NMTCNeuroOne Medical Technologies2.1931 of 5 stars$0.68-0.3%$1.45+113.8%-9.1%$33.88M$5.76M-3.0820Positive NewsGap UpCOCHEnvoy Medical2.7861 of 5 stars$1.42-7.2%$9.25+551.4%-37.0%$32.63M$212K-1.0334TMDIFTitan MedicalN/A$0.29flatN/A+600.0%$32.62M$17.63M-0.2350 Related Companies and Tools Related Companies Nephros Competitors Safe Pro Group Competitors electroCore Competitors Precision Optics Competitors QT Imaging Competitors Modular Medical Competitors PolyPid Competitors NeuroOne Medical Technologies Competitors Envoy Medical Competitors Titan Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAVM) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
